NAMES DAVID HEIMBROOK
VICE PRESIDENT,ONCOLOGY RESEARCH AND GLOBAL HEAD, ONCOLOGYRoche, a leading research-based pharmaceutical company, today announced the appointment of David C. Heimbrook, Ph.D., as vice president, Oncology Research and Global Therapy Area Head, Oncology.In his new position, Heimbrook will lead oncology research in Nutley and be responsible for creating oncology research strategy and for portfolio assessment and risk evaluation of global oncology milestones. "David brings with him an impressive scientific background, a proven level of achievement in drug discovery and outstanding leadership abilities," said Lee Babiss, Ph.D., vice president, Preclinical Research and Development.
Their global commitment to oncology provides a great opportunity for drug development, and I'm honored to be selected to lead this discovery effort," said Heimbrook
.Prior to joining Roche, Heimbrook had been with Merck Research Laboratories since 1986 where he held positions of increasing responsibility, most recently as Executive Director and Head of the Department of Cancer Research.In this capacity, he led a substantial department of scientists through all phases of drug development and coordinated worldwide multi-site efforts in cancer research and drug discovery in Europe and Japan. Heimbrook
has co-authored 52 published manuscripts and review articles, 10 U.S. patent applications and three Investigational New Drug Applications.He graduated from Duke University, Summa Cum Laude, with a B.A. in Chemistry and was elected to the Phi Beta Kappa Honor Society.He
also received his
M. Phil. and Ph.D. in Biochemistry from Yale University.Heimbrook
family plan to relocate to New Jersey.